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Abstract
Background: The early diagnosis of atherosclerotic disease is essential for developing preventive
strategies in populations at high risk and acting when the disease is still asymptomatic. A low ankle-
arm index (AAI) is a good marker of vascular events and may be diminished without presenting
symptomatology (silent peripheral arterial disease). The aim of the PERART study (PERipheral
ARTerial disease) is to determine the prevalence of peripheral arterial disease (both silent and
symptomatic) in a general population of both sexes and determine its predictive value related to
morbimortality (cohort study).
Methods/Design: This cross-over, cohort study consists of 2 phases: firstly a descriptive,
transversal cross-over study to determine the prevalence of peripheral arterial disease, and
secondly, a cohort study to evaluate the predictive value of AAI in relation to cardiovascular
morbimortality.
From September 2006 to June 2007, a total of 3,010 patients over the age of 50 years will be
randomly selected from a population adscribed to 24 healthcare centres in the province of
Barcelona (Spain).
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BMC Public Health 2007, 7:348 http://www.biomedcentral.com/1471-2458/7/348The diagnostic criteria of peripheral arterial disease will be considered as an AAI < 0.90,
determined by portable Doppler (8 Mhz probe) measured twice by trained personnel.
Cardiovascular risk will be calculated with the Framingham-Wilson tables, with Framingham
calibrated by the REGICOR and SCORE groups. The subjects included will be evaluted every 6
months by telephone interview and the clnical history and death registries will be reviewed. The
appearance of the following cardiovascular events will be considered as variables of response:
transitory ischaemic accident, ictus, angina, myocardial infartction, symptomatic abdominal
aneurysm and vascular mortality.
Discussion: In this study we hope to determine the prevalence of peripheral arterial disease,
especially the silent forms, in the general population and establish its relationship with
cardiovascular morbimortality. A low AAI may be a better marker of arterial disease than the
classical cardiovascular risk factors and may, therefore, contribute to improving the predictive
value of the equations of cardiovascular risk and thereby allowing optimisation of multifactorial
treatment of atherosclerotic disease.
Background
Prevention and early diagnosis of atheroslerotic disease is
one of the essential objectives of the field of cardiovascu-
lar disease since it is the main cause of mortality in devel-
oped countries. In Spain, cardiovascular diseases are the
first cause of death, producing 34% of all deaths [1], with
ischaemic heart disease causing the greatest number of
cardiovascular deaths (31%) followed by cerebrovascular
disease (29%) [1].
Atherosclerosis is currently considered a chronic, progres-
sive, systemic disease, the genesis of which involves com-
plicated pathogenic mechanisms. This disease is
characterised by remaining clinically silent during most of
its evolutive process until the sudden appearance of com-
plications of the atherosclerotic plaques which lead to
ischaemic vascular events. From primary prevention point
of view, it is therefore very important to develop strategies
to identify patients with subclinical stages of arteriosclero-
sis.
Atherosclerotic disease is characterised by a multifactorial
aetiology constituted by different risk factors which
potentiate among themselves and which are often pre-
sented in asssociation [2]. Risk factors which may be mod-
ified include arterial hypertension, hypercholesterolemia,
diabetes mellitus, and smoking, while age and sex are non
modifiable factors. Other risk factors act through interme-
diate risk factors such as abdominal obesity [3,4], seden-
tarism, or a family history of early coronary heart disease.
These risk factors have been integrated in prediction tables
based on regression models with the aim of detecting the
population at high risk of presenting cardiovascular
events [5]. However, the sensitivity and positive predictive
value of these tables is low and, thus, most cardiovascular
diseases are produced in persons without a high risk [5].
It is, therefore, important to develop markers of silent ate-
riosclerotic disease which may aid to better define the
patients at high risk and to thereby act early and inten-
sively to prevent the appearance of cardiovascular diseases
with pharmacologic and non pharmacologic measures.
The ankle-arm index (AAI) is the result of the quotient
obtained by dividing systolic arterial pressure (SAP) at the
level of the posterior pedial or tibial artery between the
brachial SAP by Doppler [6]. Low values of AAI determi-
nation (<0.9) allow the diagnosis of peripheral arterial
disease (PAD) in asymptomatic patients [7]. An AAI of <
0.9 has a sensitivity of 95% and a specificity of 99% for
angiographically demonstrated PAD [8]. Determination
of the AAI also allows the quantification of the severity of
PAD: mild (AAI = 0.7 – 0.9), moderate (AAI = 0.5 – 0.69)
and severe stenosis (AAI = <0.5).
In some studies a low AAI has shown to be a good marker
of vascular events [8]. In the Atherosclerosis Risk in Com-
munities (ARIC) Study [9,10], the AAI was inversely asso-
ciated with coronary disease, ictus and atherosclerosis at
the level of the carotid and popliteal arteries. The Edin-
burgh Artery Study [11] reported a relative risk of ictus of
1.98 (CI 95%; 1.05 – 3.77) in patients with an AAI < 0.9.
In a Swedish cohort of males over the age of 68 years [12]
followed over 10 years, the relative risk of ischaemic ictus
for an AAI = 0.9 was 2.0 (95% CI; 1.1 – 3.7). These results,
however, do not agree in all studies. In the Cardiovascular
Health Study [7], an assocation was found between a low
AAI and the risk of vascular events in general, but no rela-
tionship was observed between an AAI < 0.9 and the risk
of ictus. In addition, in the Pittsburgh study the risk of car-
diovasscular events significantly increased only above an
AAI < 0.7 [13].
Another aspect requiring clarification is the prognostic
value of AAI in a medium with a low prevalence of cardi-
ovascular diseases such as in Spain and other Mediterra-
nean countries [14].Page 2 of 7
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BMC Public Health 2007, 7:348 http://www.biomedcentral.com/1471-2458/7/348Moreover, the PAD is a significant predictor of cardiovas-
cular mortality [15-17]. Mortality is also greater in
patients with asymptomatic PAD compared to patients
without arterial disease [16,18,19]. Some studies [7] have
suggested that PAD in females represents a greater cardio-
vascular morbidity while in males this disease represents
a higher mortality rate.
The prevalence of PAD ranges between 1.8% and 25%
according to the population, the medium studied and the
cut-off value of the AAI [11,20-25]. Likewise, the preva-
lence is higher in determined populational subgroups
such as diabetics [20] and smokers [23]. No populational
based studies are available in Spain, with the studies
found being carried out in selected populations [26-34].
The present study will have two phases. The main objec-
tive of the first phase (cross-over study) is to determine the
prevalence of PAD in the general population, in both its
silent and symptomatic forms. The secondary objective is
to study the association of PAD, especially in the silent
forms, with other prevalent cardiovascular events and car-
diovascular risk factors. The main objective of the second
phase (cohort study) is to determine the incidence of car-
diovascular events in patients with PAD and quantify the
risk of having these events. The secondary objective in this
phase is to study the predictive value of AAI with respect
to the risk of having cardiovascular events in relation to
the equations of cardiovascular risk (Framingham-Wil-
son, Framingham calibrated by REGICOR and SCORE).
Methods/Design
This is a two-phase study. The first phase is a transversal,
multicentre, descriptive study the aim of which is to deter-
mine the prevalence of symptomatic and asymptomatic
PAD in a general population attended in primary care. The
secondary aim is to study the association of PAD, espe-
cially in the silient forms, with other previous or prevalent
cardiovascular events and cardiovascular risk factors. The
second phase is a cohort study, the main objectives of
which are to determine the incidence of cardiovascular
events in patients with and without PAD and to quantify
the risk of having these events. The secondary objective is
to study the predictive value of AAI with respect to the risk
of having cardiovascular events in relation to the equa-
tions of cardiovascular risk (Framingham, Framinham
calibrated by REGICOR and SCORE). An initial 5-year fol-
low up will be carried out in the cohorts generated in
phase I: subjects without PAD and subjects with PAD and
the cardiovascular morbimortality will be analysed. This
study has been approved by the local Ethics Committee
(Jordi Gol i Gurina Foundation of Investigation in Pri-
mary Care). Informed written consent will be obtained
from all the participants. Likewise, the recommendations
of the World Medical Assocation Declaration of Helsinki
will be followed [35].
Setting
This study will be performed in a total of 24 healthcare
centres within the metropolitan area of the city of Barce-
lona and the county of North Barcelona – Maresme,
including urban and semi-rural healthcare centres. These
centres cover a population of approximately 600,000
inhabitants.
Study Population and subjects
A simple randomised sample will be undertaken until
achieving the required sample size. Figure 1 provides a
flow diagram of the study.
Data collection
Data will be collected in a questionnaire specifically
designed for this study. Prior to initiation of the study a
pilot trial will be performed in 120 cases to detect errors
in its design, to test the questionnaire interviewers and to
verify concordance in data collection (data validation).
Baseline data collections (cross-over study)
The following variables will be studied.
-Demographic, cultural and economic variables related to
the capacity of physical strength, with a previously vali-
dated questionnaire [36], related to menopause, family
history of early cardiovascular death, personal history of
cardiovascular disease, acute myocardial infarction,
angina, cerebrovascular accident [14]. Similarly, the clini-
cal history will be verified if the patient is diagnosed with
ictus (CIE 10 code: I64), transitory ischaemic accidents
(CIE 10 code: G45), angina (CIE 10 code: I20.0), acute
myocardial infarction (CIE 10 code: I25) and PAD of the
lower extremities (CIE 10 code: I73.9). Personal history of
hypercholesterolemia, diabetes mellitus, arterial hyper-
tension and smoking, establishing the history and current
status of the smoking habit in the latter case [14,37-39].
-Anthropometric variables, current systolic/diastolic
blood pressure values, blood analysis (total cholesterol,
HDL-cholesterol, DLD-cholesterol, triglycerides and gly-
caemia [glycosylated haemoglobin (HbA1c) in diabetics],
except in the case of having a recent analysis within the
last 12 months, and standard electrocardiogramme [40].
Calculation of cardiovascular risk with the Framingham-
Wilson equations [40], Framingham calibrated by the
REGICOR [41] and SCORE [42] groups, and medications
taken considering current drug intake (at least 1 tablet/
day) of the following pharmacological groups: lipid-low-
ering drugs, antiaggregants, anticoagulants, antihyperten-
sives and hypoglycidemiants [43,44]; Edinburgh vascular
questionnaire [45].Page 3 of 7
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BMC Public Health 2007, 7:348 http://www.biomedcentral.com/1471-2458/7/348The ankle-arm index (AAI) examination of the subjects
will be carried out in the 24 healthcare centres participat-
ing in the study by two healthcare professionals trained in
the technique. The AAI will be performed in the two par-
amaleolar arteries of both lower extremities, taking into
consideration the lowest of four AAI determinations. If
the result is < 0.9, the technique will be performed by the
other professional. In cases in which the second profes-
sional finds an AAI>= 0.9, the first will repeat the test and
the latter value will be considered as the final result. AAI
measurement will be performed by the standardised pro-
cedure [6].
Patients with peripheral arterial disease will be referred to
the general practitioner of the healthcare centre to which
the patient is adscribed to follow the protocols of the cen-
tre. If the AAI is lower than 0.5, the patient will be referred
to the vascular surgeon of reference.
Follow up (cohort study)
After determination of the AAI the subject will enter in
one of the cohorts (AAI>= 0.9: cohort without peripheral
arterial disease; AAI < 0.9 cohort with peripheral arterial
disease).
The successive controls will be undertaken every 6 months
after the last visit, by telephone interview. The appearance
Flow diagram of the studyigure 1
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BMC Public Health 2007, 7:348 http://www.biomedcentral.com/1471-2458/7/348of any of the events will be registered in the data collection
protocol: transitory ischaemic accident, ictus, angina,
myocardial infarction, symptomatic abdominal aneurysm
and mortality attributable to vascular causes.
The main variable of response will be the appearance of
cardiovascular events as a combined compound variable
[27] made up of the following diseases:
Morbidity
-Coronary disease: 1) angina, 2) acute myocardial infarc-
tion
-Cerebrovascular disease: 1) transient ischaemic attack, 2)
ictus
-Symptomatic aneurysm of the abdominal aorta
These events will be confirmed by a cardiologist, neurolo-




-Sudden death attributable to cardiovascular events
-Aneurysm of the abdominal artery
-Complications of PAD.
The mortality will be studied by: control of the computer-
ised clinical history, telephone interview with a relative
and personal or telephone interview with general practi-
tioner responsible for the patient. If adequate information
is not obtained by the above sources, the emergency
departments (SEM) and emergency paramedical services
(061) and, if necessary, the statistical registries of deaths
(Department of Health) will be consulted.
Statistical analysis
Sample size
The sample size for the cohort study has been calculated
with an alpha risk of 0.05, a beta risk of 0.20 in a bilateral
contrast, taking a relationship of exposure (altered AAI)
compared to no exposure (normal AAI) of 1:9 into
account. To do this 301 subjects in the group of patients
diagnosed with peripheral arterial disease (pathologic
AAI) and 2709 patients in the group without peripheral
arterial disease (normal AAI) are required to detect a min-
imum relative risk of the main variable of response of 2,
accepting an incidence of the cardiovascular disease stud-
ied in the general population of 5.2% [24]. The rate of loss
to follow up has been calculated to be of 10%.
This sample size also ensures correct estimation of the
populational prevalence of asymptomatic AAI in our
medium with a precision of 2%, accepting an alpha risk of
0.05 in the most unfavourable case of having to detect a
prevalence of 50%.
Data analysis
This will be performed with the Stata 9 statistical package
after the introduction of the data in a database (Acces).
Quantitative variables will be compared with the Stu-
dent's t test and analysis of variance (ANOVA) will be per-
formed, using the corresponding non parametric tests
when necessary. Qualitative variables comparisons will be
determined using the Chi squared test.
An analysis of survival of each vascular event will be per-
formed according to the presence/absence of PAD with
the Kaplan-Meier curves. Cox multivariate regression
models will be used to compare the probability of having
a cardiovascular event in the follow up cohorts, adjusting
for the necessary covariables. The relative risk (hazards
ratio) will be analysed with a confidence interval of 95%.
Discussion
The aim of the PERART study is to evaluate the real preva-
lence of peripherial arterial disease in the general popula-
tion which remains to be determined in Spain and is
poorly known in countries with a low cardiovascular risk.
These data will be the main contribution of this study
since, to date only data of series of patients and very
selected populations have been established.
With the present study we hope to demonstrate that the
silent forms of peripheral arterial disease may be a marker
of cardiovascular risk with a better adjustment than the
methods based on risk tables since these are indicative of
real damage in the cardiovascular system still in presymp-
tomatic stages.
It is therefore important to keep in mind that the AAI may
have a predictive value which is higher than the tradi-
tional methods of calculating cardiovascular risk since
these methods are based on probabilistic mathematical
equations while the AAI detects early stages of atheroscle-
rotic disease. On being a systemic disease, the detection of
peripheral involvement is probably indicative of asymp-
tomatic involvement of other vascular territories, and
thus, the determination of AAI may have diagnostic and
prognostic significance in the detection of asymptomatic
cerebrovascular disease. Another interesting aspect is the
follow up of the patients with a high AAI, which may also
indicate a certain risk of having cardiovascular events if
associated with arterial calcification [32].Page 5 of 7
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BMC Public Health 2007, 7:348 http://www.biomedcentral.com/1471-2458/7/348If the results confirm our hypothesis we will have an easy,
accessible, inexpensive test, which is reproducible in Pri-
mary Care and which will allow a better selection of
patients in whom an approach of greater therapeutic
intensity may be applied to thereby avoid or slow major
cardiovascular complications and events. We may then
have a test to allow screening for selecting patients prior
to performing more complex tests or to decide whether to
intensify the interventions in lifestyle or with drugs (stat-
ins, acetylsalicillic acid, etc.)
On the other hand, the populational, multicentric, pro-
spective design of the study, which collects most of the
cardiovascular risk factors will allow our cohort to be used
to verify the validity of the existing cardiovascular risk fac-
tors or those of other similar future projects within the age
range of this study.
The PERART study may have certain limitations such as
not including a population of under the age of 50 years
because of the high prevalence of PAD in this age group.
Likewise, according to the different studies the variability
of the calculation of the AAI between previously trained
observers is 7% [46]. To reduce the interobserver variabil-
ity to a minumun, the AAI will only be performed by two
specially trained healthcare professionals.
The sensitivity of the AAI as a predictor of vascular events
is low (compared to the specificity). Nonetheless, it will
probably be greater than the traditional methods of calcu-
lating cardiovascular risk. The Framingham tables and
REGICOR are designed to calculate cardiovascular risk in
patients between 35 and 74 years in age. In patients > 74
years we will calculate the risk assigning the score corre-
sponding to 74 years (maximum risk for age). On the
other hand, we will be working with symptomatic dis-
eases and thus the patients will be receiving medication,
which may modify the natural history of the disease.
However, it would not be ethical to discontinue antiaggre-
gant treatment in subjects with a diminished AAI. This
means that any effect of PAD with respect to the appear-
ance of cardiovascular events will be lower than that pro-
voked by PAD left to its natural evolution without
diagnosis or treatment.
In conclusion, the PERART study will attempt to deter-
mine the prevalence of PAD in a low cardiovascular risk,
Spanish population, and especially, to determine the pre-
dictive value of pathologic AAI in relation to the risk of
having cardiovascular disease since it may be a better
marker than the classical cardiovascular risk factors
because of its being indicative of the presence of arterial
lesion.
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